Clinical Trial Update: Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating MEDI-507 in CD2-positive lymphoma and leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• MEDI-507

Snippet

Sponsor: MedImmune LLC | Conditions: Lymphoma, Leukemia | Phase 1 | Status: TERMINATED